10-Q: American Shared Hospital Services Reports Q1 2025 Results: Revenue Up, But Net Loss Incurred

American Shared Hospital Services (ASHS) saw revenue increase in Q1 2025, driven by direct patient services, but reported a net loss due to lower Gamma Knife and PBRT volumes and increased operating costs.

Summary

• American Shared Hospital Services reported a net loss of $625,000, or $0.10 per diluted share, for the three months ended March 31, 2025, compared to a net income of $119,000, or $0.02 per diluted share, for the same period last year.
• Total revenues increased by $896,000 to $6,112,000, driven by a $2,158,000 increase in direct patient services revenue to $3,121,000, primarily from the RI Companies acquisition and the Puebla facility.
• Leasing segment revenue decreased by $1,262,000 to $2,991,000 due to lower Gamma Knife and PBRT volumes.
• PBRT revenue decreased by $1,007,000 to $1,642,000, with PBRT fractions down by 445 to 831.
• Gamma Knife revenue decreased by $471,000 to $2,096,000, with procedures down by 65 to 208.
• Total costs of revenue increased by $2,097,000 to $5,170,000, driven by higher maintenance, depreciation, and operating costs.
• Selling and administrative expenses decreased by $71,000 to $1,808,000.
• Interest expense increased by $84,000 to $433,000 due to increased borrowings.
• The company had cash, cash equivalents, and restricted cash of $11,491,000 at March 31, 2025, compared to $11,275,000 at December 31, 2024.
• The company borrowed $2,000,000 on its Revolving Line as of March 31, 2025.
• The company has commitments to purchase and install three Leksell Gamma Knife Esprit Systems and two Linear Accelerator (LINAC) systems, totaling $9,618,000.
• The company is in compliance with its debt covenants as of March 31, 2025, but received a waiver from DFC for certain covenants as of December 31, 2024, and through December 31, 2025.

Sentiment

Score: 4

Explanation: The report indicates mixed performance. Revenue increased, but the company incurred a net loss. There are also concerns about debt and compliance with covenants. The outlook is uncertain, resulting in a slightly negative sentiment.

Positives

• Total revenues increased by $896,000 to $6,112,000 for the three-month period ended March 31, 2025 compared to $5,216,000 for the same period in the prior year.
• Direct patient services revenue increased by $2,158,000 to $3,121,000 for the three-month period ended March 31, 2025 compared to $963,000 for the same period in the prior year.
• Selling and administrative expense decreased by $71,000 to $1,808,000 for the three-month period ended March 31, 2025 compared to $1,879,000 for the same period in the prior year.
• The company is in compliance with its debt covenants as of March 31, 2025.

Negatives

• The company reported a net loss attributable to American Shared Hospital Services increased by $744,000 to a loss of $625,000, or $0.10 per diluted share for the three-month period ended March 31, 2025 compared to net income of $119,000, or $0.02 per diluted share for the same period in the prior year.
• Revenues from the Companys leasing segment decreased by $1,262,000 to $2,991,000 for the three-month period ended March 31, 2025 compared to $4,253,000 for the same period in the prior year.
• Revenues generated from the Companys PBRT system decreased by $1,007,000 to $1,642,000 for the three-month period ended March 31, 2025 compared to $2,649,000 for the same period in the prior year.
• Gamma Knife revenue decreased by $471,000 to $2,096,000 for the three-month period ended March 31, 2025 compared to $2,567,000 for the same period in the prior year.
• Total costs of revenue increased by $2,097,000 to $5,170,000 for the three-month period ended March 31, 2025 compared to $3,073,000 for the same period in the prior year.
• Interest expense increased by $84,000 to $433,000 for the three-month period ended March 31, 2025 compared to $349,000 for the same period in the prior year.
• Interest and other income, net, decreased by $42,000 to $64,000 for the three-month period ended March 31, 2025 compared to $106,000 for the same period in the prior year.

Risks

• The company's level of debt could impact its ability to operate its business.
• The limited market for the company's capital-intensive services could affect revenue.
• Lowered federal reimbursement rates could negatively impact revenue.
• U.S. health care reform legislation could have an impact on the company.
• Competition and alternatives to the company's services could affect market share.
• Technological advances and the risk of equipment obsolescence could require significant capital expenditures.
• The company's significant investment in the proton beam radiation therapy business carries risk.
• Restrictions in the company's debt agreements limit its flexibility to operate its business.
• The company's ability to repay its indebtedness is not guaranteed.
• The company's ability to integrate the RI Companies with its existing business is not guaranteed.
• Breaches in security of the company's information technology could disrupt operations.
• The small and illiquid market for the company's stock could affect investors.
• There can be no assurance that financing will be available for the Companys current or future projects, or at terms that are acceptable to the Company.

Future Outlook

The company expects Newco in Guadalajara, Mexico, to begin treating patients in the fourth quarter of 2025. The company intends to finance substantially all of its commitments to purchase and install three Leksell Gamma Knife Esprit Systems and two Linear Accelerator (LINAC) systems.

Industry Context

The company operates in the stereotactic radiosurgery and advanced radiation therapy equipment and services market. The industry is influenced by factors such as reimbursement rates, technological advancements, and healthcare regulations. The company competes with other providers of similar equipment and services.

Comparison to Industry Standards

• It is difficult to compare ASHS directly to industry standards due to its unique business model of providing turn-key technology solutions rather than directly competing with hospitals and cancer centers.
• However, companies like Elekta and Varian Medical Systems are major players in the radiation therapy equipment market, and their financial performance can provide some context.
• Elekta, as the manufacturer of the Gamma Knife, is a key partner and competitor, and its performance in the radiosurgery market is relevant.
• GenesisCare, from whom ASHS acquired the RI Companies, is a large provider of radiation therapy services, and its financial struggles highlight the challenges in the direct patient services segment.

Management Changes

Related Party Transactions

• The company had significant related party transactions with Elekta, the manufacturer of the Gamma Knife, including equipment purchases, commitments to purchase and service equipment, and costs to maintain the equipment.
• Equipment purchases and de-install costs from related parties totaled $1,307,000 for the three months ended March 31, 2025.
• Costs incurred to maintain equipment from related parties totaled $251,000 for the three months ended March 31, 2025.
• The company also had commitments to purchase and install three Esprit units, two LINACs, and service the related equipment of $14,869,000 as of March 31, 2025.

Stakeholder Impact

• Shareholders: The net loss and decrease in earnings per share could negatively impact shareholder value.
• Employees: The company's performance could affect employee morale and job security.
• Customers: The company's ability to provide services and maintain equipment could impact customer satisfaction.
• Suppliers: The company's financial performance could affect its ability to meet its obligations to suppliers.
• Creditors: The company's debt levels and compliance with covenants are important to creditors.

Next Steps

• The company plans to install three Leksell Gamma Knife Esprit Systems and two Linear Accelerator (LINAC) systems.
• The company expects Newco in Guadalajara, Mexico, to begin treating patients in the fourth quarter of 2025.
• The company intends to hire experienced staff to manage the billing cycle for its Rhode Island facilities internally, expected around the fourth quarter of 2025.
• The company will continue to assess the need for additional resources, especially in the finance and accounting areas, as the Companys business continues to grow and expand.

Key Dates

Keywords

Gamma Knife, PBRT, Radiation Therapy, Medical Equipment Leasing, Direct Patient Services, Healthcare, ASHS, American Shared Hospital Services